The bill pitted the two largest companies headquartered in Indianapolis—drugmaker Eli Lilly and Co. and health insurer Anthem Inc.—on opposite sides of the issue.
Lilly signs deal to sell $210M worth of COVID-19 antibodies to U.S. government
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.Read More
Lilly quarterly profit surges, helped by new COVID-19 treatment
The antibody treatment bamlanivimab was Lilly’s second-highest selling product in the final quarter of 2020, trailing only the popular diabetes drug Trulicity.Read More
Eli Lilly, Glaxo join forces to test COVID-19 antibody cocktail
GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Indianapolis-based Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can better combat the virus and its variants together.Read More
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Josh Smiley, Lilly’s CFO since 2018, resigned from the company after the drugmaker said he had engaged in a improper personal relationship with an employee.
The combo treatment is the second COVID-19 antibody therapy from the Indianapolis-based drugmaker to gain an emergency authorization from the FDA.
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
The Indianapolis-based drugmaker said people from minority communities are frequently “unseen” by the U.S. health care system.
Several other Indiana companies also say they are suspending contributions to all candidates or are taking a close look at the matter.
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
CVS has developed a program to provide the treatments in their homes, but it won’t be available—at least initially—in Indianapolis.
In a separate development, the FDA on Thursday gave emergency authorization to use of another anti-inflammatory drug sold by Eli Lilly, baricitinib, to be used with remdesivir.
The Indianapolis drugmaker said Thursday evening it was awarded an emergency use authorization for its drug baricitinib to be used in combination with Gilead Sciences’ antiviral drug remdesivir in severely ill, hospitalized patients with COVID-19.
Because of the initial limited supply, the number of doses each state receives will be determined by the number of confirmed cases and hospitalizations in a given week, federal officials said.